ASIA

The region is the largest contributor to the Group’s Sterile Focus Brands revenue and comprises all Asian territories including China. Active trading subsidiaries include those in China, the Philippines, Taiwan, and Malaysia with other countries and territories in the region such as Hong Kong reached via distributors. The region has one manufacturing site in Hyderabad, India, which is focused on new product development.

Key Countries

China
India
Malaysia
Philippines

KEY COUNTRIES AND TERRITORIES

Brand		Therapeutic category
Arixtra		Antithrombotic agent
Diprivan		General anaesthetic
Fraxiparine		Low molecular weight heparin
Naropin		Regional anaesthetic
Ultiva		Injectable general anaesthetic

NUMBER OF PERMANENT EMPLOYEES

1 166

June 2022

1 214

June 2021

STATISTICS

Number of products launched:

3

(2021: 3)

Number of product recalls:

Nil

(2021: Nil)

Average staff turnover:

29%

(2021: 24%)

Number of work-related fatalities:

Nil

(2021: Nil)

Sales representatives:

535

(2021: 574)

Revenue	2022 R’million	2021 (CER) R’million	Change %
Commercial Pharmaceuticals	5 116	5 127	0
Regional Brands	613	614	0
Sterile Focus Brands	4 503	4 513	0
Manufacturing – API Chemicals	112	75	49
Total	5 228	5 202	0

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue is by place of manufacture.

China’s pharmaceutical market including hospital and retail channels is expected to grow at 2,4% CAGR (2021 to 2026). The market is expected to be valued at RMB1,234 billion by 2026.
The Korea total pharmaceutical market grew 8,2% MAT Q1 2022 versus Q1 MAT 2021.

Source: IQVIA Market Prognosis 2022M03 & IQVIA MAT 2022 Q1 Vs MAT 2021 Q1
MAT = Moving annual total.